Stockscreener 앱 받기
16.65
2.97%
-0.51
시간 외 거래:
16.76
0.11
+0.66%
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst - Stocktwits
Sarepta cleared to re-submit sNDAs for Amondys and Vyondys - The Pharma Letter
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
Sarepta (SRPT) sNDA Filing Indicates Positive Outlook - GuruFocus
Oppenheimer Reiterates "Outperform" Rating for Sarepta Therapeutics (SRPT) | SRPT Stock News - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer - MarketBeat
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure - BioSpace
Sarepta (SRPT) Plans sNDA Submissions for Duchenne Therapies - GuruFocus
Sarepta plans regulatory submissions for two Duchenne drugs by April 2026 - StreetInsider
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® - itemonline.com
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
KROS: Is the Discount Book Value a Value Trap? - TradingView
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study - TradingView
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - BioSpace
Sarepta (SRPT) Advances ENDEAVOR Study with New Cohort - GuruFocus
Sarepta announces that screening and enrollment are underway in Endeavor cohort 8 to evaluate enhanced immunosuppression regimen as part of Elevidys gene therapy for non-ambulant individuals with Duchenne - marketscreener.com
Sarepta begins trial testing sirolimus with gene therapy - Investing.com
Sarepta begins enrollment for enhanced safety protocol in gene therapy study - StreetInsider
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy - Yahoo Finance
Price-Driven Insight from (SRPT) for Rule-Based Strategy - Stock Traders Daily
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness - simplywall.st
Boxer Capital Management LLC Increases Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Braidwell LP Makes New Investment in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup - TipRanks
Union Square Park Capital Management LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Quinn Opportunity Partners LLC Increases Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Director Sells $123,207.78 in Stock - MarketBeat
Sarepta Therapeutics (SRPT) Maintains 'Outperform' Rating as Mizuho Raises Price Target | SRPT Stock News - GuruFocus
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty - Citeline News & Insights
Sarepta Therapeutics (SRPT) Maintains 'Outperform' Rating as Miz - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Buys 1,129,610 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
First Trust Advisors LP Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Tax withholding trims Sarepta (NASDAQ: SRPT) EVP's stock stake - Stock Titan
Reporting person files to sell restricted SRPT shares (SRPT) - Stock Titan
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Sarepta (SRPT) CFO has 275 shares withheld to cover RSU tax - Stock Titan
Sarepta (NASDAQ: SRPT) exec has 1,399 shares withheld for taxes - Stock Titan
Sarepta (SRPT) COO has 1,619 shares withheld to cover RSU taxes - Stock Titan
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Sarepta (NASDAQ:SRPT) Healthcare Tech Buzz In Nasdaq Composite - Kalkine Media
Citigroup Raises Price Target for SRPT but Maintains Sell Rating - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Given New $9.00 Price Target at Citigroup - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Market Sentiment Tied To Nasdaq Futures - Kalkine Media
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Why Is uniQure Stock Skyrocketing Monday? - Benzinga
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death - MSN
Sarepta shares drop after EU regulators reject Elevidys gene therapy - MSN
Sarepta shares drop after FDA asks for more data on Elevidys - MSN
Sarepta Changes Course, Agrees to Pause Elevidys Shipments - MSN
Assessing Sarepta Therapeutics (SRPT) Valuation After A Difficult Year For Shareholders - Yahoo Finance
Sarepta Therapeutics Stock Pre-Market (+4.7%): Rebounds With Market on Easing Geopolitical Fears - Trefis
SRPT Earnings History & Surprises | EPS & Revenue Results | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
Sarepta Stock Pre-Market (+4.7%): Sector Read-Across Ahead of Key Medical Conferences - Trefis
Biopharma’s recent string of CEO splits - Pharma Voice
A Look At Sarepta Therapeutics (SRPT) Valuation After Elevidys Launch Updates And Recovery Story Analyst Commentary - Sahm
Sarepta Therapeutics (SRPT) Is Down 7.0% After CEO Retirement Plan And ELEVIDYS Japan Launch NewsHas The Bull Case Changed? - Sahm
(SRPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
SRPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jefferies Maintains Buy on Sarepta Therapeutics (SRPT) March 03, 2026 - Meyka
Sarepta (SRPT) COO Estepan reports PSU vesting and tax share withholding - Stock Titan
SRPT: 2026 revenue targets remain solid as clinical and commercial initiatives advance toward 2027 - TradingView
SRPT SEC FilingsSarepta Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty - TipRanks
Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight - GuruFocus
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year - TipRanks
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo Finance
1.20%
0.06%
자본화:
|
볼륨(24시간):